Physician profile
John Walton
NPI 1417376534
$3,619.24
in general payments reported to CMS, 2019-2025
37 companies · $1,181 in 2025
The $1,181 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $851 · 2020: $112 · 2021: $119 · 2022: $446 · 2023: $502 · 2024: $409 · 2025: $1,181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Travel and Lodging: $591 · Education: $5.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.34 |
| Travel and Lodging | $590.83 |
| Education | $5.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $908.43 | 2019-2022 | |
| Medtronic, INC. | $786.03 | 2025 | Altaviva, Interstim |
| Calyxo, INC. | $229.31 | 2025 | Cvac Aspiration System |
| Pfizer INC. | $188.48 | 2023-2025 | |
| Astellas Pharma US INC | $166.68 | 2020-2025 | Xtandi, Myrbetriq |
| Axonics, INC. | $159.81 | 2022-2023 | Axonics |
| Procept Biorobotics Corporation | $149.12 | 2023 | Aquabeam Robotic System |
| Sumitomo Pharma America, INC. | $113.48 | 2023-2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $70.81 | 2022-2024 | Erleada, Akeega |
| Genzyme Corporation | $69.92 | 2020-2023 | |
| Myriad Genetic Laboratories, INC. | $69.50 | 2021-2022 | |
| Coloplast Corp | $65.52 | 2023-2024 | Speedicath |
| Progenics Pharmaceuticals, INC. | $52.71 | 2022-2024 | Pylarify |
| Antares Pharma, INC. | $48.39 | 2022-2023 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $45.83 | 2023-2024 | Keytruda, Lynparza |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $43.90 | 2024 | |
| Urovant Sciences INC | $43.44 | 2022 | |
| Atricure, INC. | $39.44 | 2019-2022 | |
| Myovant Sciences INC. | $31.44 | 2022 | |
| Dendreon Pharmaceuticals LLC | $27.73 | 2024 | Provenge |
| Clarus Therapeutics INC. | $26.86 | 2021 | |
| Endo Pharmaceuticals INC. | $25.06 | 2020 | |
| Vertex Pharmaceuticals Incorporated | $24.54 | 2024 | |
| Accord Healthcare, INC. | $24.27 | 2024 | |
| Endo USA, INC. | $21.03 | 2024 | Aveed, Xiaflex |
| Tolmar, INC. | $20.31 | 2023 | |
| Abbvie INC. | $19.36 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.76 | 2024 | |
| Astrazeneca Pharmaceuticals Lp | $17.76 | 2024 | Lynparza |
| Immunitybio, INC. | $17.44 | 2024 | |
| Laborie Medical Technologies Corp. | $16.29 | 2025 | |
| Alexion Pharmaceuticals, INC. | $15.56 | 2020 | |
| Tolmar Pharmaceuticals, INC. | $15.23 | 2021 | |
| Koelis INC. | $15.12 | 2023 | |
| Hologic Sales and Service, LLC | $14.62 | 2024 | Aptima |
| Neotract INC. | $12.50 | 2019 | |
| Travere Therapeutics, INC. | $5.56 | 2025 | Thiola |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Walton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.